search
Back to results

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Primary Purpose

Pancreatic Adenocarcinoma, Adenosquamous Carcinoma, Pancreatic Neuroendocrine Tumor

Status
Not yet recruiting
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
ESK981
Sponsored by
University of Michigan Rogel Cancer Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pancreatic Adenocarcinoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Eligibility Criteria: Patients with histological or cytological confirmation of advanced cancer per specific cohort. Cohort 1: Pancreatic adenocarcinoma or adenosquamous carcinoma who have progressed or deemed intolerant of the standard of care chemotherapy regimens. Cohort 2: Pancreatic or gastrointestinal neuroendocrine tumor or carcinoma with Ki-67 > 20% who have progressed or deemed intolerant of at least first-line standard of care systemic therapy. Cohort 3: The subject has histologically proven prostate cancer who have progressed or deemed intolerant of at least first-line standard of care systemic therapy with radiologic evidence of metastases and at least one of the following: Small cell or neuroendocrine morphology on the basis of tissue sample. Prostate adenocarcinoma with IHC staining for neuroendocrine markers (e.g., chromogranin and synaptophysin). Presence of visceral metastases or high-volume disease (> 4 sites of metastases) with a PSA ≤ 5. Serum chromogranin A level ≥ 5x upper limit of normal (ULN) and/or serum neuron specific enolase (NSE) ≥ 2x ULN. Trans-differentiated carcinoma or poorly-differentiated carcinoma Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2 Must be ≥ 18 years of age. Evaluable disease determined using guidelines of Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) Ability to understand and willingness to sign IRB-approved informed consent. Willing to provide archived tissue, if available, from a previous diagnostic biopsy. Must be able to tolerate CT and/or MRI with contrast. At least 4 weeks from major surgery with resolution of any sequela to date of enrollment Laboratory values ≤2 weeks during screening must be: Platelet count ≥ 75,000 cells/mm3 Absolute neutrophil count ≥ 1500 cells/mm3 Hemoglobin ≥ 9 g/dL AST/ALT ≤ 3x upper limit of normal [ULN], or (≤ 5x ULN if liver metastasis present) Bilirubin ≤ 1.5x ULN, or (≤ 2.5 x ULN for subjects with Gilbert's syndrome) Albumin ≥ 3 g/dL Serum creatinine clearance CrCl ≥ 50 mL/min per Cockcroft-Gault Formula INR ≤ 1.5 (or <2.0 if on anticoagulants) Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must agree to use acceptable highly effective contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive(s), intrauterine hormone releasing system (IUS), bilateral tubal occlusion or vasectomized partner) during and for 9 months after last study dose and must have a negative serum or urine pregnancy test during screening. Males with female partners (of childbearing potential) and female partners (of childbearing potential) with male partners must agree to use double barrier contraceptive measure (a combination of male condom with either cap, diaphragm or sponge with spermicide) in addition to oral contraception, or avoidance of intercourse during the study and for 6 months after last study dose is received. Female patients must not be pregnant, have a positive pregnancy test, breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 9 months after the last dose of study treatment. Male patients must be willing to abstain from donating sperm during treatment and for 6 months after completion of study treatment. No evidence of active infection and no serious infection within the past 30 days. Patient must have completed antibiotic course. No known cerebral metastasis, central nervous system (CNS), or epidural tumor (unless previously treated, asymptomatic and stable for at least 3 months). No active heart disease including but not limited to myocardial infarction that is <3 months prior to registration, symptomatic congestive heart failure (NYHA class 3 or 4), symptomatic coronary artery disease, symptomatic angina pectoris. No history of acute cerebrovascular disease, arterial embolism, pulmonary embolism, percutaneous angioplasty, or coronary artery bypass surgery within 6 months prior to registration. No pre-existing coagulopathy, or serious bleeding within 3 months prior to registration. No prior malignancy except for the following: adequately treated basal or squamous cell skin cancer, in situ cancer, localized prostate cancer (Gleason score <8), or adequately treated cancer from which the patient has been disease-free for at least 3 years prior to registration. Must not have uncontrolled diarrhea at the time of enrollment. Patients must not use a chronic daily medication known to be a strong or moderate inhibitor of CYP1A2, CYP2C8 or CYP3A4 at registration (as per Appendix II). Patients must have recovered to baseline or ≤ grade 1 CTCAE v5.0 from toxicities related to any prior treatments, unless adverse event(s) is deemed clinically non-significant and/or stable on supportive therapy. Patients must not have uncontrolled hypertension defined as blood pressure >150/90 despite optimal medical management. No known hypersensitivity to gelatin or lactose monohydrate.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Experimental

    Experimental

    Arm Label

    Cohort 1

    Cohort 2

    Cohort 3

    Arm Description

    Pancreatic adenocarcinoma

    Pancreatic or gastrointestinal neuroendocrine neoplasms with Ki-67 > 20%

    Neuroendocrine prostate carcinoma with Ki-67 > 20%

    Outcomes

    Primary Outcome Measures

    Progression Free Survival
    Determining efficacy using proportion of patients alive and progression-free at 4 months within each cancer subtype

    Secondary Outcome Measures

    Overall Response Rate (ORR) within each cancer subtype
    The ORR will be assessed per RECIST v1.1 criteria (Cohort 1 and 2) or combined RECIST v1.1 + PCWG3 criteria (Cohort 3). Partial or complete response will require confirmation on repeat scan at least 4 weeks from initial radiologic response
    Duration of Response (DoR) within each cancer subtype
    DoR will be measured from the start date of the best response achieved until the date of relapse (i.e., progression). Continuing responders will be right-censored as of the most recent date on which their response status had been assessed. DoR applies to only the patients who achieve either a complete response or a partial response.
    Overall Survival (OS) within each cancer subtype
    The OS will be defined from the date of treatment to either date of death or censoring and estimated using the product-limit method of Kaplan and Meier. Follow-up time will be censored at the date of last disease evaluation.
    Safety and tolerability in each cancer subtype
    Adverse events (AEs) will be defined per the NCI Common Toxicity Criteria for Adverse Events (CTCAE) v5.0.
    Median Progression- Free Survival (PFS) within each cancer subtype
    The PFS will be defined as time from date of initial treatment to date of radiological or clinical progression (leading to withdrawal from the study treatment), or death from any cause on study treatment, whichever comes first. Follow-up time will be censored at the date of last disease evaluation.

    Full Information

    First Posted
    August 4, 2023
    Last Updated
    August 4, 2023
    Sponsor
    University of Michigan Rogel Cancer Center
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05988918
    Brief Title
    Multicenter Trial of ESK981 in Patients With Select Solid Tumors
    Official Title
    A Phase II Multicenter Trial of ESK981 in Patients With Select Solid Tumors
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 2023 (Anticipated)
    Primary Completion Date
    August 2026 (Anticipated)
    Study Completion Date
    September 2028 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University of Michigan Rogel Cancer Center

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    Yes

    5. Study Description

    Brief Summary
    This protocol will enroll patients with pancreatic adenocarcinoma and adenosquamous carcinoma (Cohort 1), gastrointestinal/pancreatic neuroendocrine neoplasms with Ki-67 > 20% (Cohort 2) and neuroendocrine prostate carcinoma (Cohort 3)). Each cohort will have its own interim analysis after enrollment of 10 patients. Subjects will be given a one-month (28 day) supply of study drug (ESK981). Subjects will be instructed to take 4 capsules, with or without food, once per day for 5 consecutive calendar days, then take a drug holiday for 2 consecutive days before repeating the 5 days on-2 days off cycle in sets of 4 weeks or 28 calendar days. Subjects will be asked to keep a pill diary noting the date they take their study drug.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pancreatic Adenocarcinoma, Adenosquamous Carcinoma, Pancreatic Neuroendocrine Tumor, Pancreatic Neuroendocrine Carcinoma, Gastrointestinal Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Carcinoma, Neuroendocrine Prostate Carcinoma

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    66 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Cohort 1
    Arm Type
    Experimental
    Arm Description
    Pancreatic adenocarcinoma
    Arm Title
    Cohort 2
    Arm Type
    Experimental
    Arm Description
    Pancreatic or gastrointestinal neuroendocrine neoplasms with Ki-67 > 20%
    Arm Title
    Cohort 3
    Arm Type
    Experimental
    Arm Description
    Neuroendocrine prostate carcinoma with Ki-67 > 20%
    Intervention Type
    Drug
    Intervention Name(s)
    ESK981
    Other Intervention Name(s)
    CEP-11981
    Intervention Description
    160 mg, PO, Once daily 5 days on and 2 days off
    Primary Outcome Measure Information:
    Title
    Progression Free Survival
    Description
    Determining efficacy using proportion of patients alive and progression-free at 4 months within each cancer subtype
    Time Frame
    4 months after initiating study drug
    Secondary Outcome Measure Information:
    Title
    Overall Response Rate (ORR) within each cancer subtype
    Description
    The ORR will be assessed per RECIST v1.1 criteria (Cohort 1 and 2) or combined RECIST v1.1 + PCWG3 criteria (Cohort 3). Partial or complete response will require confirmation on repeat scan at least 4 weeks from initial radiologic response
    Time Frame
    up to 18 months from treatment discontinuation
    Title
    Duration of Response (DoR) within each cancer subtype
    Description
    DoR will be measured from the start date of the best response achieved until the date of relapse (i.e., progression). Continuing responders will be right-censored as of the most recent date on which their response status had been assessed. DoR applies to only the patients who achieve either a complete response or a partial response.
    Time Frame
    up to 18 months from treatment discontinuation
    Title
    Overall Survival (OS) within each cancer subtype
    Description
    The OS will be defined from the date of treatment to either date of death or censoring and estimated using the product-limit method of Kaplan and Meier. Follow-up time will be censored at the date of last disease evaluation.
    Time Frame
    up to 18 months from treatment discontinuation
    Title
    Safety and tolerability in each cancer subtype
    Description
    Adverse events (AEs) will be defined per the NCI Common Toxicity Criteria for Adverse Events (CTCAE) v5.0.
    Time Frame
    up to 30 days from treatment discontinuation
    Title
    Median Progression- Free Survival (PFS) within each cancer subtype
    Description
    The PFS will be defined as time from date of initial treatment to date of radiological or clinical progression (leading to withdrawal from the study treatment), or death from any cause on study treatment, whichever comes first. Follow-up time will be censored at the date of last disease evaluation.
    Time Frame
    up to 18 months from treatment discontinuation

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Eligibility Criteria: Patients with histological or cytological confirmation of advanced cancer per specific cohort. Cohort 1: Pancreatic adenocarcinoma or adenosquamous carcinoma who have progressed or deemed intolerant of the standard of care chemotherapy regimens. Cohort 2: Pancreatic or gastrointestinal neuroendocrine tumor or carcinoma with Ki-67 > 20% who have progressed or deemed intolerant of at least first-line standard of care systemic therapy. Cohort 3: The subject has histologically proven prostate cancer who have progressed or deemed intolerant of at least first-line standard of care systemic therapy with radiologic evidence of metastases and at least one of the following: Small cell or neuroendocrine morphology on the basis of tissue sample. Prostate adenocarcinoma with IHC staining for neuroendocrine markers (e.g., chromogranin and synaptophysin). Presence of visceral metastases or high-volume disease (> 4 sites of metastases) with a PSA ≤ 5. Serum chromogranin A level ≥ 5x upper limit of normal (ULN) and/or serum neuron specific enolase (NSE) ≥ 2x ULN. Trans-differentiated carcinoma or poorly-differentiated carcinoma Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2 Must be ≥ 18 years of age. Evaluable disease determined using guidelines of Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) Ability to understand and willingness to sign IRB-approved informed consent. Willing to provide archived tissue, if available, from a previous diagnostic biopsy. Must be able to tolerate CT and/or MRI with contrast. At least 4 weeks from major surgery with resolution of any sequela to date of enrollment Laboratory values ≤2 weeks during screening must be: Platelet count ≥ 75,000 cells/mm3 Absolute neutrophil count ≥ 1500 cells/mm3 Hemoglobin ≥ 9 g/dL AST/ALT ≤ 3x upper limit of normal [ULN], or (≤ 5x ULN if liver metastasis present) Bilirubin ≤ 1.5x ULN, or (≤ 2.5 x ULN for subjects with Gilbert's syndrome) Albumin ≥ 3 g/dL Serum creatinine clearance CrCl ≥ 50 mL/min per Cockcroft-Gault Formula INR ≤ 1.5 (or <2.0 if on anticoagulants) Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must agree to use acceptable highly effective contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive(s), intrauterine hormone releasing system (IUS), bilateral tubal occlusion or vasectomized partner) during and for 9 months after last study dose and must have a negative serum or urine pregnancy test during screening. Males with female partners (of childbearing potential) and female partners (of childbearing potential) with male partners must agree to use double barrier contraceptive measure (a combination of male condom with either cap, diaphragm or sponge with spermicide) in addition to oral contraception, or avoidance of intercourse during the study and for 6 months after last study dose is received. Female patients must not be pregnant, have a positive pregnancy test, breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 9 months after the last dose of study treatment. Male patients must be willing to abstain from donating sperm during treatment and for 6 months after completion of study treatment. No evidence of active infection and no serious infection within the past 30 days. Patient must have completed antibiotic course. No known cerebral metastasis, central nervous system (CNS), or epidural tumor (unless previously treated, asymptomatic and stable for at least 3 months). No active heart disease including but not limited to myocardial infarction that is <3 months prior to registration, symptomatic congestive heart failure (NYHA class 3 or 4), symptomatic coronary artery disease, symptomatic angina pectoris. No history of acute cerebrovascular disease, arterial embolism, pulmonary embolism, percutaneous angioplasty, or coronary artery bypass surgery within 6 months prior to registration. No pre-existing coagulopathy, or serious bleeding within 3 months prior to registration. No prior malignancy except for the following: adequately treated basal or squamous cell skin cancer, in situ cancer, localized prostate cancer (Gleason score <8), or adequately treated cancer from which the patient has been disease-free for at least 3 years prior to registration. Must not have uncontrolled diarrhea at the time of enrollment. Patients must not use a chronic daily medication known to be a strong or moderate inhibitor of CYP1A2, CYP2C8 or CYP3A4 at registration (as per Appendix II). Patients must have recovered to baseline or ≤ grade 1 CTCAE v5.0 from toxicities related to any prior treatments, unless adverse event(s) is deemed clinically non-significant and/or stable on supportive therapy. Patients must not have uncontrolled hypertension defined as blood pressure >150/90 despite optimal medical management. No known hypersensitivity to gelatin or lactose monohydrate.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Cancer AnswerLine
    Phone
    1-800-865-1125
    Email
    CancerAnswerLine@med.umich.edu
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Vaibhav Sahai
    Organizational Affiliation
    University of Michigan
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Multicenter Trial of ESK981 in Patients With Select Solid Tumors

    We'll reach out to this number within 24 hrs